Phase 3 trial in 242 adults with type 1 diabetes and CKD: finerenone cut urinary albumin-to-creatinine ratio 25% more than placebo over 6 months (P<0.001); hyperkalaemia 10.1% vs 3.3%, with a 2.9 ml/min greater eGFR fall.
RCTn = 242
Heerspink et al. Finerenone in Type 1 Diabetes and Chronic Kidney Disease